3-(5H-chromeno[2,3-b]pyridin-7-yl)-butan-2-one | 55693-51-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: 3-(5H-chromeno[2,3-b]pyridin-7-yl)-butan-2-one
• 英文别名: 3-(5h-[1]benzopyrano[2,3-b]pyridin-7-yl)-2-butanone；3-(5H-chromeno[2,3-b]pyridin-7-yl)butan-2-one
• CAS: 55693-51-1
• 化学式: C₁₆H₁₅NO₂
• 分子量: 253.301
• InChiKey: KPJFFYORLQCZFO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  39.2
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-(5H-chromeno[2,3-b]pyridin-7-yl)-butan-2-one 在 sodium hypochlorite 、 盐酸 作用下， 以 四氢呋喃 、 水 为溶剂， 以92 %的产率得到普拉洛芬杂质K
  参考文献：
  名称：

  CN116284020

  摘要：

  公开号：
• 作为产物：
  描述：

  1-(5H-chromeno[2,3-b]pyridin-7-yl)-propan-2-one 生成 3-(5H-chromeno[2,3-b]pyridin-7-yl)-butan-2-one
  参考文献：
  名称：

  NAKANISI, MITIO;OEH, TAKANORI

  摘要：

  DOI：

文献信息

• Tricycle substituted acetones
  申请人：Yoshitomi Pharmaceutical Industries, Ltd.

  公开号：US03974168A1

  公开（公告）日：1976-08-10

  Compounds of the formula: ##SPC1## Wherein Of X.sup.1 and X.sup.2 is a hydrogen atom, a halogen atom or an alkyl group having 1 to 4 carbon atoms; R.sup.1 is a hydrogen atom, an alkyl group having 1 to 4 carbon atoms, an alkenyl group having 2 to 4 carbon atoms, an alkynyl group having 2 to 4 carbon atoms or a group -B.sup.1 -R.sup.3 (wherein B.sup.1 is an alkylene group having 1 to 4 carbon atoms, and R.sup.3 is a carboxyl group, an alkoxycarbonyl group in which the alkoxy moiety has 1 to 4 carbon atoms, an alkoxy group having 1 to 4 carbon atoms or a di-alkyl-amino group in which each alkyl moiety has 1 to 4 carbon atoms); R.sup.2 is an alkyl group having 1 to 4 carbon atoms or a group -B.sup.2 -R.sup.4 (wherein B.sup.2 is an alkylene group having 2 to 4 carbon atoms, and R.sup.4 is a carboxyl group or a di-alkyl-amino group in which each alkyl moiety has 1 to 4 carbon atoms); A is a methylene group or a carbonyl group; Y is an oxygen atom, a sulfur atom or an alkyl-imino group in which the alkyl moiety has 1 to 4 carbon atoms; and Ring P is a pyridine ring; and Pharmaceutically acceptable salts thereof are disclosed. They are useful as anti-inflammatory agents, analgesics, antipyretics and antirheumatics.

  该化合物的公式为：## SPC1 ## 其中X1和X2是氢原子，卤素原子或具有1至4个碳原子的烷基; R1是氢原子，具有1至4个碳原子的烷基，具有2至4个碳原子的烯基，具有2至4个碳原子的炔基或-B1-R3（其中B1是具有1至4个碳原子的烷基，而R3是羧基，具有1至4个碳原子的烷氧羰基，具有1至4个碳原子的烷氧基或每个烷基都具有1至4个碳原子的双烷基氨基基）; R2是具有1至4个碳原子的烷基或-B2-R4（其中B2是具有2至4个碳原子的烷基，而R4是羧基或每个烷基都具有1至4个碳原子的双烷基氨基基）; A是亚甲基或羰基; Y是氧原子，硫原子或碳原子数量为1至4的烷基亚胺基; Ring P是吡啶环;以及其药学上可接受的盐。它们可用作抗炎药，镇痛剂，退烧剂和抗风湿药。
• [EN] METHOD FOR PREPARING PRANOPROFEN AND COMPOSITION CONTAINING PRANOPROFEN AND IMPURITY<br/>[FR] PROCÉDÉ DE PRÉPARATION DE PRANOPROFÈNE ET COMPOSITION CONTENANT DU PRANOPROFÈNE ET DES IMPURETÉS<br/>[ZH] 制备普拉洛芬的方法、包含普拉洛芬和杂质的组合物
  申请人：SHENYANG XINGQI PHARMACEUTICAL CO LTD

  公开号：WO2022267945A1

  公开（公告）日：2022-12-29

  本发明属于医药领域，涉及一种制备普拉洛芬的方法。本发明还涉及包含普拉洛芬和杂质的组合物、质控方法，以及合成普拉洛芬的中间体化合物及其制备方法。本发明的方法克服了现有技术的不足，缩短合成路线、降低工艺条件、精简工艺操作、提高劳动安全、更适用于工业化生产、对环境更友好、收率更高。
• NAKANISI, MITIO;OEH, TAKANORI
  作者：NAKANISI, MITIO、OEH, TAKANORI

  DOI：——

  日期：——
• NITROOXYDERIVATIVES FOR USE IN THE TREATMENT OF MUSCULAR DYSTROPHIES
  申请人：Nicox S.A.

  公开号：EP1978947B1

  公开（公告）日：2014-08-13
• NOVEL COMPOUNDS DERIVED FROM TAURINE, PROCESS OF THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE
  申请人：Vizioli Ednir de Oliveira

  公开号：US20110118303A1

  公开（公告）日：2011-05-19

  The present invention relates to compounds derived from taurine with non-steroidal anti inflammatory activity. In a first embodiment, the present invention relates to compounds derived from taurine, in which taurine is bound directly by means of an amide bond or through an spacing group, to a compound selected from the group of non-steroidal anti inflammatory compounds, cited as derived from taurine presenting the Formula (I): in which R means the component with non-steroidal anti inflammatory activity. In a second embodiment, the invention provides a process for obtaining the compounds of Formula (I) by reaction of taurine with a compound belonging to the group of non-steroidal anti inflammatory (NSAIs), in order to obtain a compound derived from taurine by direct bond or through a spacing group of the taurine to the NSAI. The invention also relates to the pharmaceutical compositions comprising at least one compound derived from taurine presenting non-steroidal anti inflammatory activity.